Active	Status	Sponsor type	Region	Phase	Filter
7 Active 0 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

7 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Kurkjian, Carla
NCT05234177: Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays	Recruiting	N/A	160	US	Observation	Tempus AI	Colorectal Cancer	02/25	02/27
NCT05236114: GEMINI-NSCLC: NSCLC Biomarker Study	Recruiting	N/A	813	US	Observation	Tempus AI, AstraZeneca	Non-Small Cell Lung Cancer	06/25	02/27
Tummala, Mohan
NCT05234177: Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays	Recruiting	N/A	160	US	Observation	Tempus AI	Colorectal Cancer	02/25	02/27
NCT05236114: GEMINI-NSCLC: NSCLC Biomarker Study	Recruiting	N/A	813	US	Observation	Tempus AI, AstraZeneca	Non-Small Cell Lung Cancer	06/25	02/27
O'Brien, Laura
SY-1425-202, NCT04905407: Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed AML	Recruiting	2	95	Europe, US	Tamibarotene, Venetoclax, Venclexta, Azacitidine, Vidaza	Syros Pharmaceuticals	Acute Myeloid Leukemia	04/28	04/28
NCT05236114: GEMINI-NSCLC: NSCLC Biomarker Study	Recruiting	N/A	813	US	Observation	Tempus AI, AstraZeneca	Non-Small Cell Lung Cancer	06/25	02/27
Ostronic, Carla
NCT05236114: GEMINI-NSCLC: NSCLC Biomarker Study	Recruiting	N/A	813	US	Observation	Tempus AI, AstraZeneca	Non-Small Cell Lung Cancer	06/25	02/27